A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Public ClinicalTrials.gov record NCT07217171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas
Study identification
- NCT ID
- NCT07217171
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- EvolveImmune United, Inc
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
- Anal Squamous Cell Carcinoma
- Bladder Cancer
- Cervical Squamous Cell Carcinoma
- Cutaneous Squamous Cell Cancer
- Esophageal Squamous Cell Carcinoma
- Penile Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Lung
- Tongue Squamous Cell Carcinoma
- Urethral Squamous Cell Carcinoma
- Vaginal Squamous Cell Carcinoma
- Vulvar Squamous Cell Carcinoma
Interventions
- EVOLVE104 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2025
- Primary completion
- Jan 28, 2029
- Completion
- Jan 28, 2031
- Last update posted
- Apr 12, 2026
2025 – 2031
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| Yale University Cancer Center | New Haven | Connecticut | 06511 | Recruiting |
| The Winship Cancer Institute Emory University | Atlanta | Georgia | 30322 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | Recruiting |
| SCRI | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07217171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07217171 live on ClinicalTrials.gov.